Fairvalue-Calculator Fairvalue-Calculator
EN DE

Nuvectis Pharma, Inc (NVCT) Fair Value & Analysis

Healthcare · US · Market cap $367M

Price$17.55
Fair Value$3.12
Upside-82.2%
Quality95/100
Evidence: Low Range $2.34 – $3.90

Fair value as of: Jun 24, 2026

Analysis

Nuvectis Pharma, Inc (NVCT) currently trades at $17.55, while our model-based Fair Value estimate is $3.12 — implying the stock looks roughly 82.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Nuvectis Pharma, Inc (NVCT) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $3.12 versus a price of $17.55 — about −82% (overvalued). Model-based estimate, not financial advice.
What is the fair value of NVCT?
Our 21-model fair value for Nuvectis Pharma, Inc is $3.12 (as of Jun 24, 2026), built from audited fundamentals. The current price is $17.55.
What is the quality score of NVCT?
Nuvectis Pharma, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.